Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ifida...This paragraph explains a bit of the connection here:
In addition, ReliaGene is a pioneer in the development of Y-STR testing, a technology which profiles genetic markers on the male Y chromosome. In 2003, the lab used this technology to provide the crucial piece of evidence linking South Louisiana serial killer suspect Derrick Todd Lee to a sixth homicide (Geralyn DeSoto). No doubt this case contributed heavily to ReliaGene’s selection for “Best Application of Technology.”
This is great news...
Later,
W2P
ice105...Nothing new...Reprints of both the 10k filing from April and the latest shareholder newsletter. Oh, and a page of coupons for AncestryByDNA...lol
BTW, I just got mine yesterday in the mail...
Later,
W2P
mingwan0...I'm confused. There are those on the other board that are asserting that "the other shoe is about to drop", and that Dr. Frudakis is looking to abandon DNAPrint. Do you have an explanation as for his agreeing to speak at this conference in November 2004 on behalf of DNAPrint if he will no longer be an employee?
Thanks,
W2P
mingwan0...Based on this filing, it appears that Dr. Frudakis would be considered an "independent" director of the company. If I'm not mistaken, isn't that one of the requirements for AMEX or NASDAQ listing?
Thanks,
W2P
Speculation...
Are these related?
DNAPrint Wins FAMRI Research Grant
Thursday February 20, 9:43 am ET
SARASOTA, Fla., Feb. 20 /PRNewswire-FirstCall/ -- DNAPrint (OTC Bulletin Board: DNAP - News; the "Company"), the world leader in the measurement of population structure for disease genetics, personalized medicine and forensics profiling, announced today that it has been awarded part of a 2-year grant worth $200,000 to study population genetic links between cervical disease and Environmental Tobacco Smoke (ETS).
The award was made by the Flight Attendants Medical Research Institute (FAMRI), which was established as part of the $300M tobacco settlement finalized in 1997. The grant, titled "Genetic Susceptibility to Cervical Cancer in Second Hand Smokers", was written in collaboration with the University of Miami School of Medicine to mirror a study the Company and the University executed last year. That study was successful in identifying genetic markers of variable first-line response to paclitaxel/carboplatin chemotherapy, and led to the development of OVANOME, the Company's first chemopredictive product.
The ultimate objective of the funded work is genomics-empowered disease prevention. There is considerable evidence that invasive cervical cancer arises from intraepithelial neoplasia (CIN) and that human papillomavirus (HPV) is involved in this initiation. However, HPV infection alone is clearly insufficient to fully explain CIN, and evidence suggests that ETS exposure is a contributing risk factor. The study funded today will employ DNAPrint's innovative approach for whole-genome screening (ADMIXMAP) to identify gene variants linked to this risk. A successful outcome could lead to a better understanding of the environmental and heritable mechanisms for CIN and, eventually, to the development of new preventative drugs and genomics-based tests.
http://www.leespharm.com/EN/news/news_1875.html
Approval received to initiate clinical study on cervicitis for Yallaferon
(Hong Kong, 7 November 2003) Lee's Pharmaceutical Holdings Limited (GEM Stock: 8221; Website: www.leespharm.com) today announced that the approval was just received from the State Food and Drug Administration of the People's Republic of China to initiate clinical study on cervicitis for its flagship product Raw recombinant human Ï«-2b interferon gel¯ - Yallaferon.
Cervicitis is very common, affecting more than half of all women at some point during their adult lives. Human papillomaviruses (HPV¯) and herpes virus are the most common virus found in cervicitis, which can lead to cervical cancer. If the cervicitis is caused by infection, antibiotics or antiviral medicines may be prescribed. In additions, it is sometimes necessary to destroy the inflamed tissue of the cervix which can be achieved by cryosurgery, electrocauterization and laser therapy. However, the high recurrence rate, vaginal discharge or vaginal bleeding after surgery have made the methods undesirable.........
The reason I ask is:
http://www.prbpharmaceuticals.com/virology/additional.asp
Additional Virology Group Products
Yallaferon
Yallaferon is a proprietary preparation of interferon for topical use developed by and licensed from Lees Pharmaceuticals (HK). Yallaferon is for the treatment of condyloma acuminata (genital warts, being a kind of wart) and other superficial viral infections such as herpes. Yallaferon has successfully completed a 141-patient clinical trial organized by Beijing Medical University The First Hospital in August 1999. Prior to the launch of Yallaferon, the available route of administration on interferon for treatment of viral infection was by way of injection only. However, for diseases, such as genital warts, which is superficial and spot-focused in nature, it is difficult to apply high enough concentration of interferon locally by way of systemic injection without causing signficant side effects. Yallaferon, which is in gel form, can be applied locally and directly to the infection site.
Later,
W2P
Speculation...
Are these two related?
http://biz.yahoo.com/bw/040422/226216_1.html
Sun City Industries Enters into Reorganization Agreement with China Based Biotech & Pharmaceutical Company
Thursday April 22, 10:16 pm ET
Agreement Signed With Yangling Daiying Biological Engineering Co., Ltd.
APOPKA, Fla.--(BUSINESS WIRE)--April 22, 2004-- Sun City Industries, Inc. (OTCBB: SCII - News) has entered into a Reorganization Agreement with Yangling Daiying Biological Engineering Co., Ltd., a corporation organized under the laws of the People's Republic of China. Daiying has developed the world's very first Hepatitis C virus (HCV) culture that retains biological activity in vitro. The Reorganization Agreement is conditional upon the signing of a consulting agreement, warrant agreement and the completion of various schedules to be part of the Reorganization Agreement. A closing date has not yet been set but the parties are striving to close in April 2004. Sun City will be filing an 8K to satisfy its reporting requirements under Regulation FD and the Exchange Act of 1934 as amended. The Reorganization Agreement will be provided as an exhibit to the 8K.
And this:
http://www.prbpharmaceuticals.com/news/attachment/Lai_release.pdf
Dr. Lai has also been at the forefront of research on the hepatitis C virus. He lead the scientific team that discovered that the hepatitis virus can mimic one of the molecular targets of interferon, the body’s naturally occurring antiviral agent, blocking its ability to kill viruses. This finding has served as a cornerstone of research to develop effective therapies to combat hepatitis C.
I only mention it because of this:
http://www.prbpharmaceuticals.com/company/management.asp
Hector J. Gomez, M.D., Ph.D., Chief Medical Officer, Head of Research and Development.
Dr. Gomez has over twenty years of experience in the biopharmaceutical industry. From 1994-1999, as President and CEO of Transcend Therapeutics, a biotechnology company in Cambridge, MA, Dr. Gomez defined its strategic planning and oversaw its implementation. He led the transition from a private to a public company (IPO). He was also CEO of Zengen, Inc., a private Biotech Company in California. Before joining Transcend, he was Vice President of Medical Affairs for Vertex Pharmaceuticals in Cambridge, MA, where he was responsible for planning and implementing the Pre-Clinical, Clinical Research and Regulatory Affairs departments. Prior to that he was a senior executive for two large pharmaceutical companies: Executive Director, Cardiovascular for Ciba-Geigy in Summit, NJ, and before that, Senior Director, Cardiovascular Clinical Research for Merck in Rahway, NJ. Dr. Gomez received an M.D. from the National University of Colombia, and a Ph.D. from Marquette University and a Diploma in Clinical Pharmacology from Tulane University.
Later,
W2P
SlopsterSlasher...The study you cited is from early 2004. IMO, Dr. Sturm's involvement with pigmentation research and the University's involvement in researching melanoma risk phenotypes may help explain DNAPrint's decision to terminate their relationship with the Penn State Research Foundation in February of 2004. Perhaps they located a collaborator with more direct research experience in their area of interest:
http://hmg.oupjournals.org/cgi/content/abstract/13/4/447
Human Molecular Genetics, 2004, Vol. 13, No. 4 447-461
DOI: 10.1093/hmg/ddh043
Interactive effects of MC1R and OCA2 on melanoma risk phenotypes
David L. Duffy1, Neil F. Box2, Wei Chen2, James S. Palmer1,2, Grant W. Montgomery1, Michael R. James1, Nicholas K. Hayward1, Nicholas G. Martin1 and Richard A. Sturm2,*
1Queensland Institute of Medical Research, Brisbane, Australia and 2Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
Received October 21, 2003; Accepted December 11, 2003
The relationships between MC1R gene variants and red hair, skin reflectance, degree of freckling and nevus count were investigated in 2331 adolescent twins, their sibs and parents in 645 twin families. Penetrance of each MC1R variant allele was consistent with an allelic model where effects were multiplicative for red hair but additive for skin reflectance. Of nine MC1R variant alleles assayed, four common alleles were strongly associated with red hair and fair skin (Asp84Glu, Arg151Cys, Arg160Trp and Asp294His), with a further three alleles having low penetrance (Val60Leu, Val92Met and Arg163Gln). These variants were separately combined for the purposes of this analysis and designated as strong ‘R’ (OR=63.3; 95% CI 31.9–139.6) and weak ‘r ’ (OR=5.1; 95% CI 2.5–11.3) red hair alleles. Red-haired individuals are predominantly seen in the R/R and R/r groups with 67.1 and 10.8%, respectively. To assess the interaction of the brown eye color gene OCA2 on the phenotypic effects of variant MC1R alleles we included eye color as a covariate, and also genotyped two OCA2 SNPs (Arg305Trp and Arg419Gln), which were confirmed as modifying eye color. MC1R genotype effects on constitutive skin color, freckling and mole count were modified by eye color, but not genotype for these two OCA2 SNPs. This is probably due to the association of these OCA2 SNPs with brown/green not blue eye color. Amongst individuals with a R/R genotype (but not R/r), those who also had brown eyes had a mole count twice that of those with blue eyes. This suggests that other OCA2 polymorphisms influence mole count and remain to be described.
Later,
W2P
mingwan0...You remember our good buddy Stephen O'Brien, Chief of the Laboratory of Genomic Diversity at the NCI. Here's what he had to say just this past January 2004:
http://www.sptimes.com/2004/01/11/Tampabay/Race_gleaned_from_DNA.shtml
...But some genetics experts say that the test is a scam, that it couldn't possibly yield the results it claims for the price it costs and that it could be used to try to bolster racist claims.
"The company will be able to provide you with an estimate, but it won't be much better than looking at the guy," said Stephen J. O'Brien, chief of the Laboratory of Genomic Diversity at the National Cancer Institute in Frederick, Md. "I'm sure it won't have much use to the recipient..."
"...Stephen O'Brien, the National Cancer Institute laboratory chief, said there's plenty to question. He called the test a scam.
Different ethnic groups carry a "proportion" of distinctive genes, but they represent a tiny fraction of the overall variation.
"Put simply, there is 10 to 20 times more genetic differences between any two people within one race, say Caucasian, than there are between the racial groups," O'Brien said.
In theory, he said, it is possible to create such a test, but it would be quite expensive. At DNA Print Genomics' price, he said, it would have to be "woefully inaccurate."
O'Brien also said he thought the results could be used "for no good."
"You need look no further than the apartheid rules of South Africa," he said. "If that regime had quantitative estimators of ethnicity, they would have exploited these to serve a racist agenda and discrimination..."
I wonder how long it took him to get his foot out of his mouth before he signed on to participate in the MALD admixture study you referenced. LOL
Later,
W2P
Easyman51...The first number is their relative rank for the month in terms of overall volume. I.E. MERI ranked 8th among the MM's for DNAP's overall volume for the month.
The second number is the percentage of the overall volume. DNAP traded about 50 million shares in June. 570,000 represents about 1% of the total volume.
Later,
W2P
Two New Market Makers with Activity This Month:
MERRIMAN CURHAN FORD & CO. 570,000 8 1
Not much volume for the month, but it is their first for the year. Here's the company website:
http://www.merrimanco.com/
The other was Citigroup Global Markets, Inc. (SBSH) - Salomon Smith Barney:
CITIGROUP GLOBAL MARKETS INC. 166,966 15 <1
Again, very little volume, but interesting to see them here.
As has been the pattern, Schwab is taking on an ever larger portion of the total trading volume, displacing NITE as the highest volume MM. This past month Schwab (SCHB) traded 51% of the total, with NITE a distant second with 15% of the shares traded. All the details are available here:
http://www.otcbb.com/asp/tradeact_mv.asp?Issue=dnap&searchby=issue&sortby=volume&Month=6....
Later,
W2P
mingwan0...Yes, it is fairly current, isnt' it...lol
Am J Hum Genet. 2004 May;74(5):1001-13. Epub 2004 Apr 14.
A high-density admixture map for disease gene discovery in african americans.
Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, Kessing BD, Malasky MJ, Scafe C, Le E, De Jager PL, Mignault AA, Yi Z, De The G, Essex M, Sankale JL, Moore JH, Poku K, Phair JP, Goedert JJ, Vlahov D, Williams SM, Tishkoff SA, Winkler CA, De La Vega FM, Woodage T, Sninsky JJ, Hafler DA, Altshuler D, Gilbert DA, O'Brien SJ, Reich D.
Laboratory of Genomic Diversity, National Cancer Institute, Frederick, MD, USA.
Admixture mapping (also known as "mapping by admixture linkage disequilibrium," or MALD) provides a way of localizing genes that cause disease, in admixed ethnic groups such as African Americans, with approximately 100 times fewer markers than are required for whole-genome haplotype scans. However, it has not been possible to perform powerful scans with admixture mapping because the method requires a dense map of validated markers known to have large frequency differences between Europeans and Africans. To create such a map, we screened through databases containing approximately 450000 single-nucleotide polymorphisms (SNPs) for which frequencies had been estimated in African and European population samples. We experimentally confirmed the frequencies of the most promising SNPs in a multiethnic panel of unrelated samples and identified 3011 as a MALD map (1.2 cM average spacing). We estimate that this map is approximately 70% informative in differentiating African versus European origins of chromosomal segments. This map provides a practical and powerful tool, which is freely available without restriction, for screening for disease genes in African American patient cohorts. The map is especially appropriate for those diseases that differ in incidence between the parental African and European populations.
And with the McKeigue collaboration, just announced, it appears we have moved on to remain that one step ahead that we have always been.
Later,
W2P
mingwan0...HOLY CANOLES! Is it safe to say that the scientific community, including some of our past adversaries, are "beginning" to see things OUR WAY:
Michael W. Smith,1,2 Nick Patterson,3 James A. Lautenberger,1 Ann L. Truelove,1,2 Gavin J. McDonald,3,4 Alicja Waliszewska,3,5,6 Bailey D. Kessing,1,2 Michael J. Malasky,1,2 Charles Scafe,10 Ernest Le,3 Philip L. De Jager,3,5,6 Andre A. Mignault,4 Zeng Yi,11 Guy de The´,12 Myron Essex,7 Jean-Louis Sankale´,7 Jason H. Moore,13,14 Kwabena Poku,16 John P. Phair,17 James J. Goedert,18 David Vlahov,19 Scott M. Williams,13,14,15 Sarah A. Tishkoff,20 Cheryl A. Winkler,1,2 Francisco M. De La Vega,10 Trevor Woodage,10 John J. Sninsky,21 David A. Hafler,3,5,6 David Altshuler,3,4,8,9 Dennis A. Gilbert,10 Stephen J. O’Brien,1 and David Reich,3,4
1 Laboratory of Genomic Diversity, National Cancer Institute, and 2 Basic Research Program, Science Applications International Corporation, National Cancer Institute, Frederick, MD; 3 Program in Medical and Population Genetics, Broad Institute, Cambridge, MA; 4 Department of Genetics and 5 Laboratory of Molecular Immunology, Harvard Medical School, 6 Center for Neurologic Disease, Brigham and Women’s Hospital, 7 Harvard AIDS Institute and Department of Immunology and Infectious Diseases, Harvard School of Public Health, and Departments of 8 Medicine and 9 Molecular Biology, Massachusetts General Hospital, Boston; 10 Applied Biosystems, Foster City, CA; 11 Institute of Virology, Chinese Academy of Preventive Medicine, Beijing; 12 Department of Viral Oncology-Epidemiology, Institut Pasteur, Centre National de la Recherche Scientifique, Paris; 13 Department of Molecular Physiology and Biophysics, 14 Center for Human Genetics Research, and 15 Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN; 16 School of Administration, University of Ghana, Legon, Ghana; 17 Howard Brown Health Center and Department of Medicine, Northwestern University, Chicago; 18 Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD; 19 Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York; 20 Department of Biology, University of Maryland, College Park, MD; and 21 Celera Diagnostics, Alameda, CA
HAPPY 4th of July, INDEED!
Later,
W2P
mingwan0...This company has an interesting history:
http://www.biofrontera.com/company/history.html
history
2004
Biofrontera obtains positive interim report of the adaptive Phase II clinical trial for the treatment of severe chronic urticaria
2003
Biofrontera licenses non-CNS drug discovery projects to BioAgency AG
Biofrontera enters a co-marketing agreement with Evotec OAI AG
1st closing of new VC round, lead by Heidelberg Innovation
Biofrontera acquires the entire operations of bioLeads GmbH, a natural compound company based in Heidelberg/Germany
Biofrontera signs a long-term collaboration with Schering AG (FSE: SCH, NYSE: SHR) to discover and develop new drugs for the treatment of stroke
2002
Biofrontera signs a joint drug discovery and development collaboration with Kiadis BV. The alliance focuses on novel compounds for the treatment of neuropathic pain
Biofrontera opens its integrated platform technology to potential customers
Biofrontera changes into a Holding structure with Biofrontera Pharmaceuticals GmbH as a wholly owned subsidiary
2001
Biofrontera starts own screening programs and announces a collaboration with bioLeads GmbH
Biofrontera enters a 3-year research collaboration with Johnson & Johnson (Janssen Pharmaceutica NV)
2000
Biofrontera Pharmaceuticals GmbH changes into an AG
Biofrontera and Informax begin a strategic alliance for bioinformatics software development
Biofrontera starts research collaborations with leading academic and commercial organisations in the areas of Schizophrenia, Chronic Pain and Stroke
Biofrontera raises 11.8 mln € in a second round of financing
Biofrontera completes its technology platform and starts its first drug discovery collaboration with PharmEco Inc., Lexington, MA, USA
1998
Biofrontera enters a collaboration with Ruhr-University Bochum for the construction of a specified pathogen free (SPF) animal house
Biofrontera Pharmaceuticals starts its operations on February 1st in Leverkusen, Germany. The company raises 10.9 mln € in the largest first round financing in Germany at the time
Later,
W2P
Mike...I'm certain they are aware that the needs and desires of an AncestryByDNA customer are different from those of a police agency. I would refer you to the PR announcing the upgrade to DNAWitness 2.5:
The original DNAWitness(TM) 2.0 test was capable of reporting the percentage of "European," "western sub-Saharan African," "East Asian" and "Native American" admixture from a crime scene sample, where the colloquial terms in quotes represent ancestry traced to four of the major phlyogeographic clades that constitute the human family tree. The upgraded version of the test, DNAWitness(TM) 2.5 is capable of doing the same, but in addition can determine whether a donor of primarily European admixture is of continental European, Middle Eastern or Indo-Pakistani origin, or whether an East Asian's major ethnic affiliation is Northern (Chinese/Japanese), Central Asian or South East Asian.
You might ask yourself, if they can do this with Witness, why haven't they announced the availablity of this information to their Ancestry customers. Probably for reasons as you have cited.
BTW, this would indicate that the current test, DNAWitness 2.5, is already capable of 8 distinctions.
Later,
W2P
mingwan0...I am a bit partial to fluff myself...although I must take exception to the question:
What were the stars like when you were young?
I prefer to wonder, what will they be like when I am old? lol
Later,
W2P
chig...Sorry for this, but I don't have premium features, and sent a reply during Happy Hour. Don't have any other way to know it went through. Did you get my note?
Later,
W2P
bag8ger...Interesting theory to be sure...but I'm betting it's DNAPrint. Recall the e-mail from Jerry Wicks at Senecio discussing the potential NIH collaborations with DNAP, and who could forget the company logos and picture of Sarasota in the website image files.
We'll have to keep an eye on it though...time will tell.
Later,
W2P
bag8ger...Yes, it was an e-mail from McKeigue himself telling us they were in the process of discussing a collaboration.
Later,
W2P
patiencepays...Very nicely worded. Thanks. eom
frog...I have previously expressed my thoughts that the Dutton report answered many of the questions in the shareholder list. Secondly, I believe the company has given us evidence that they are aware of the list:
http://host.wallstreetcity.com/wsc2/Autoflag.html?Button=Get+Story&DB=SQL&SID=161p0313&S....
"We are pleased to be covered by JM Dutton Associates. It is an independent review that reinforces what I saw at DNAPrint(TM) when I was invited to join the board of directors and then lead the Company as its Chief Executive Officer and President," said Richard Gabriel, CEO and President of DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP). "Over the last year, we have been reorganizing and strengthening our Company with much-needed cash flow. There is no doubt that DNAPrint has been on the cutting edge of the genomics revolution, proving that you don't need to burn hundreds of millions of dollars to build a technology foothold in an emerging market. What you do need is a dedicated team of smart researchers and managers, committed to the health and success of the Company. We are beginning to emerge from a very difficult period in the Company's development, and we are aggressively seeking opportunities to put our capital to work. What our shareholders should realize is that our recent capital raising transaction is well within line of what a traditional Venture Capital deal would take in terms of equity dilution. We are doing everything we can to help boost our shareholders' confidence and build real underlying stock values."
IMO, these statements, especially the last, speak directly to some of the questions the shareholders raised concerning the funding decision. Its inclusion in the Dutton PR, put out by the company, signalled to me that they have the list. It certainly wasn't included to address "potential" shareholders, but existing ones.
The list was first proposed as a means of allowing the company to answer investor concerns at the shareholder meeting. While I was suspicious of the intent of the people initiating the effort, I saw no harm, and to the contrary, thought there was merit in presenting a comprehensive list in advance of the meeting. However, my initial reservations are seemingly being played out now that the emphasis on the boards seems to have shifted to using it as a means to criticize corporate communications.
As a long shareholder, I am more than happy allowing the company to address the issues at the meeting. And I would respectfully suggest that to provide the answers in other than a formal company newsletter, or at the company shareholder meeting, would not be an appropriate method of disseminating information.
Finally, with the meeting only about a month away, I doubt the company is interested in presenting answers, at this time, to the myriad of questions asked. If they were to do that, it would pretty much eliminate the need for a meeting...lol I suggest that we wait.
Later,
W2P
retro...They leased some computer equipment. eom
mingwan0...Thanks, I suspected you would have much of this archived...lol
Later,
W2P
IVRT...Nope, but I just sent you a SUPER secret e-mail. Don't tell anyone...lol
Later,
W2P
Interesting Exerpts from the Moffitt Agreement:
1. SCHEDULE The Projects shall be carried out from November 17, 2003 to November 17, 2006 ("Project Period") unless sooner terminated by written notice pursuant to Section 10 of this Agreement. This Agreement may be renewed by the Parties, as a new Agreement or by amendments to this Agreement.
Interesting, the agreement wasn't announced until March 29, 2004, yet according to the agreement, the schedule started November 17, 2003. Almost as if the parties took a sneek preview prior to announcing the agreement.
3. FUNDING - Neither Party is obligated to fund the research of the other Party. Hence, Company and Moffitt shall each be responsible for their own expenses incurred in the performance of the Projects, unless otherwise agreed to in writing. Moffitt makes no representations that they will fund any clinical trials that may ensue from the Projects. Funding for the clinical trials will be dependent upon each Principal Investigator's ability to financially support such trials and or support from Company or another third party.
Funding for the research itself appears to be up to each individual party. The trials, however, seem to be looking first to the Principal Investigator and/or the Company or another third party (a pharma company perhaps?)
7.2 The Parties agree that it is in their best interest to commercialize any Joint Inventions resulting form the Projects. In the event that Joint Inventions are commercialized, the Parties agree:
7.3 Except for the granting of rights to respective governmental agencies as required by law and the offer of Terms made in this Section 7, the Parties agree that during the term of this agreement neither party will issue a license agreement or assign patent rights to any third parties without the prior written consent of the other Parties.
They intend to commercialize the results, and neither party can take the property and sidestep the other through a third party license, unless all parties agree.
PROPOSED STUDIES
DNAPRINT GENOMICS, INC. AND THE H. LEE MOFFITT CANCER CENTER RESEARCH INSTITUTE, INC. AT THE UNIVERSITY OF SOUTH FLORIDA.
GOALS
BACKGROUND
THE H. LEE MOFFITT CANCER CENTER
The H. Lee Moffitt Cancer Center - has a substantial program involved in cancer, has access to a l85,000 patient clinical center and has expertise in the conduct of clinical trials.
DNAPRINT GENOMICS, INC. - IS A PHARMACOGENOMICS COMPANY WITH PROPRIETARY TECHNOLOGIES TO STUDY DNA SAMPLES AND DETERMINE CLASSIFIERS TO PREDICT RESPONSES TO DRUGS.
STUDY PROPOSAL ON COLON CANCER
PRINCIPAL INVESTIGATOR AT MOFFITT: TIM YEATMAN, MD
STUDY PROPOSAL ON MULTIPLE MYELOMA
PRINCIPAL INVESTIGATOR AT MOFFITT: DANIEL SULLIVAN, MD
STUDY PROPOSAL ON CYCLOPHOSPHAMIDE
PRINCIPAL INVESTIGATOR AT MOFFITT: RICHARD M. LUSH, PHD
STUDY PROPOSAL ON TAXANES
PRINCIPAL INVESTIGATOR AT MOFFITT: JONATHAN M. LANCASTER, MD
I just enjoy the fact that three of the four principal investigators are, in fact, MD's.
12. TERMINATION This Agreement may be terminated by any Party at any time uponthe giving of ninety (90) days prior written notice to the other Parties.
Evidence of very serious intent. Ninety (90) days prior notice required to terminate the Agreement.
Lastly, the signatories:
Director of Technology Transfer
H. Lee Moffitt Cancer Center and Research Institute, Inc.
12902 Magnolia Drive
Tampa, Florida 33612-9497
Name: James J. Mule
Associate Center Director
Translational Science and Technology Development
Looks like they're hoping to develop some technology and transfer it for commercialization. Music to investor ears.
Later,
W2P
Robert...You have an innate ability to take a subject, boil it down to its essence, and communicate that essence to the board. Execellent post.
Thanks,
W2P
Straw5...Clearer now? Actually, no, just the opposite.
You started off this thread saying:
The most interesting thing about that series of paragraphs is that it supports the legitimacy of spook’s point of view regarding paying for ratings...
Since you believed that the "most interesting thing" about this morning's information was that it supports spook's point, I thought it important that you clarify what you mean when you say "spook's point". It just gives everyone a point of reference for the discussion. You told me you weren't going to do it, then you did it anyway:
First of all, I am not going to summarize spook’s position for anyone “here,” since anyone “here” is just a few mouse clicks away from RB and they can read it themselves.
The point of view I am referring to was stated early on by spook and I would be very surprised if you missed it. It was that you can’t have real independent analysis of your company if you in fact pay the researcher to provide it. Furthermore, that a company that makes a living providing independent analysis will not be in business for long if they rarely issue buy ratings.
That's pretty close, but you're hedging. In actuality, his opinion left NO room for anyone to accept any "compensated independent" analysis. Here let me refresh your memory. He stated it quite clearly in this early post:
(worktoplay) The entire idea of being "independent" and "compensated" is a direct conflict of interest. As soon as money changes hands, the "independent analysts" completely lose their independence.
You're intelligent enough to know this is a indisputable fact in any market. Stop being dishonest.
DNAP paid for a buy rating.
First of all, he accused me of putting forth a "dishonest" opinion, and as I've shown, if my opinion is "dishonest", it is one that is shared by Lou Thompson, President of the National Investor Relations Institute, who issued Guidelines in 2002 endorsing legitimate "paid-for" research".
Secondly, since the SEC and a wide number of organizations share Mr. Thompson's view, that places "spook" in direct opposition. So I fail to see how anything I posted this morning supports spook's view of "compensated, independent" research.
Finally, as regards your observation (or was it spook's observation - see how this get's confusing?) that:
Furthermore, that a company that makes a living providing independent analysis will not be in business for long if they rarely issue buy ratings.
This statement misses the entire point of the business strategy of companies like Dutton. They are an outlet for good, undercovered companies that need to expand awareness of their securities. The reason Dutton is thriving is because the "old boy" system of the big brokerage firms, whereby you couldn't get coverage unless you were a paying client of theirs, left thousands of good companies out there without options.
Dutton can afford to be honest, because he has good companies knocking his door down for his services. In that regard, the firm's integrity is it's greatest business asset, and as long as he's honest, independent, and accurate he'll ALWAYS have more clients than he can handle, because there will ALWAYS be good companies out there that no one's ever heard of.
Clearer now?
Later,
W2P
Robert...I will have to defer to none other than Jim Dutton:
"The more sunlight that shines on every step of the process, the better for everybody."
Hope your're enjoying a bright, sunny, day!
Later,
W2P
Straw5...That's an interesting perspective. But I'm confused about a couple of things. Perhaps you could clear them up for me so that if we continue this thread, we are both on the same page.
You said:
The most interesting thing about that series of paragraphs is that it supports the legitimacy of spook’s point of view regarding paying for ratings (as something more than "DNAP bashing" as it was portrayed). If you read the text, it is clear that these independent research companies have evolved to fill a niche:
"Given that (Wall Street) can no longer pay for research through investment banking, we're probably going to see a significant reduction in the number of companies that have any analyst coverage. So then companies are left wondering, 'How am I going to get institutional investors to let me in the door without any coverage?'"
Perhaps you could explain to me how the fact that these companies have evolved to fill a niche supports spook's point of view...and please, I would ask that you limit the discussion to Dutton, in particular, since they are the firm providing coverage to DNAPrint.
Secondly, as a purely "independent" analyst yourself, would you kindly review spook's posts regarding the Dutton coverage and summarize his position for us, since he is not here to speak for himself. I just want to make certain his point of view is fairly portrayed, and it will afford others in this forum the opportunity to form a judgement as to your objectivity and independence as an observer.
Lastly, could you please review my posts on the subject and point me to those that characterized his position as "DNAP bashing". All I remember doing was providing evidence and arguments to support Dutton as a source of solid, independent research, as evidenced by their credentials and track record. I even gave him an example of a "less than reputable" company, so that he could contrast the two, which he summarily dismissed.
Thanks, I look forward to your response.
One more thing. You said:
It appears to be an ongoing process:
While independent research by standards-based providers are growing in legitimacy, according to the Dow Jones (DJ) in a recent article, the article quoted Lou Thompson, president of the National Investor Relations Institute, which had issued new Guidelines on 2002 endorsing legitimate "paid-for" research, as warning of " various mutations of paid-for research."
Given that we are not talking about "various mutations of paid for research", the most relevant point made in the paragraph is the fact that Lou Thompson, president of the National Investor Relations Institute, had issued new Guidelines in 2002 endorsing legitimate "paid-for" research".
I would remind you that we are not talking about paid for research, in general, we are discussing JM Dutton Associates, in particular. And it has been, and to my knowledge continues to be, spook's position that the report was "Rubbish" and JM Dutton Associates is a paid for shill. I have YET to see a shred of evidence to support that view, and I have YET to see a retraction by spook of that position.
Help me understand what it is I'm not understanding here.
Later,
W2P
Cosmic...And you might also be interested in this little tidbit...Financialwire is a division of Investrend Communications. You can confirm that at the bottom of this PR from Financialwire:
http://host.wallstreetcity.com/wsc2/Autoflag.html?Button=Get+Story&DB=SQL&SID=154r4482&S....
You'll also note the familiar text.
Now, here's an older PR from Investrend. Note the analyst:
http://www.vanishpoint.com/9_24_2001.asp?section=inv
And guess WHO originally founded Investrend:
That's true to the mission Dutton set out on when he founded Investrend, another pay-for-play research organization from which he parted to start the new company, taking many of the analysts with him. "The more sunlight that shines on every step of the process, the better for everybody," Dutton holds. An avid airplane pilot and sailor in his off-hours, he knows a lot about sunlight. And about independence.
And we don't have to guess who one of the analysts was that he took with him to his new company...lol
There isn't a problem here, but I would suggest that the company contact Financialwire and get whatever beef they had cleared up. It's old baggage (no relation to bag8gage BTW...lol), and an unnecessary distraction to investors.
Later,
W2P
Cosmic...DNAPrint has been included in those Financialwire PR's for quite some time. Their inclusion has nothing to do with Dutton or the SEC. Here's a recent example. As you read the PR you will see the same text that is included in the present notice:
http://host.wallstreetcity.com/wsc2/Autoflag.html?Button=Get+Story&DB=SQL&SID=155r8021&S...
If you'd like to see some other examples go to WallStreetCity.com and look at the "Latest News" column. As you move down the list you will see the same thing repeated in a number of releases:
http://host.wallstreetcity.com/wsc2/corporate_snapshot.html?DB=SQL&template=corpsnap.htm&Sym...
I noticed it some time back, when I saw PR's that appeared to have nothing to do with DNAPrint, only to read and find the same text repeated over, and over, and over again. The oldest one on the current list is from 5/24/04, but they go back much further than that.
In fact, if I were the company I'd contact the "Financialwire" people and get this cleared up. They apparently had a beef with something the company said in a PR at one time, and will keep repeating the refrain ad infinitum. Because of that, it should be addressed, IMO.
If I were Marketing Director for DNAPrint, it is another one of those little things that I'd see was taken care of.
Later,
W2P
Theo...Thanks...lol But where's the alert? eom
Nice Finish to the Day:
http://host.wallstreetcity.com/wsc2/corporate_snapshot.html?DB=SQL&template=corpsnap.htm&Sym...
Last 10 Trades...
Later,
W2P
Robert/Grateful/frog...My reading of the report, and my opinion based on the uncertainty surrounding the FDA's role is that the initial target price was based solely on the company's ability to grow it's Forensics business.
They discounted genealogy as a major growth opportunity and spent considerable time discussing the regulatory uncertainty and potential delays related to FDA action that could impact the pharmacogenomic opportunity. IMO, that is all any competent analyst COULD do.
How, for instance, would you include the pharmaco "potential", and if you did, where would you set a target? They obviously thought that the company has interesting and unique technology, but with FDA final rulemaking a year away, and without any guidance even having been issued, what is an honest analyst to do? I think the "conclusion" summed it up well and helps to explain what they did and did not factor into the rating:
Conclusion
DNAPrint genomics holds unique technology in the emerging field of predictive genomics. We believe it is one of only a
few companies, public or private, capable of applying a cost-effective technology platform to this emerging field-and is
doing so with a steadily growing revenue stream from its commercialized products. However, in the Company’s intended target market of pharmacogenomics profile diagnostics, regulatory and potential ethical issues may arise as products in this area come to market and gain media attention. Without a doubt, pharmacogenomic profiling will be required as part of the overall battle against rising healthcare costs, but the timing of development of widespread demand for these products is as of yet, still in the midst of evolving FDA policy. In the meantime the Company will have to gain greater acceptance in the forensics market to generate revenues. Therefore, we rate DNAPrint genomics shares as a Speculative Buy.
Whadayatink?
Later,
W2P
Theo...WOW!!!!! What the heck are the chances???
http://www.usatoday.com/news/nation/2004-06-03-twins-dna_x.htm
Not aware of anything, but I wouldn't be surprised to find out that if anyone COULD, they could..lol
BTW, didn't realize you were in Grand Rapids. I play in the Portland Best Ball tournament every spring. Are you a golfer?
Later,
W2P
winbig...Then you had best take a pill. After that, READ THE REPORT. They're talking to you, even if you feel the need to scream.
When you calm down, ask yourself why a company like K2 would go to Dutton, then perhaps you'll begin to understand why DNAPrint did as well:
http://www.jmdutton.com/Research/RAWL/Reports/KTO_Report_080603.pdf
Later, much later,
W2P
winbig...You want news? READ THE REPORT...there's plenty of news there.
Later,
W2P
This is the first of a series of 4 quarterly reports commencing on 6/7/04.
Should be interesting to track the changes through the next year.
Later,
W2P
"...We are forecasting revenue of $2 million and a net loss of $8.8 million for the full year 2004..."
Later,
W2P
I wonder how to interpret this?
"...DNAPrint genomics has a partnering agreement with Orchid Biosciences..."
Does she mean the "Option"? I thought the option had been transferred to Beckman Coulter...
Later,
W2P
"...The discovery of these novel Taxol-response predictive SNPs has formed the basis for a potential collaborative agreement for the continued development of the Ovanome product...DNAPrint hopes to generate revenue with the product prior to FDA approval through sales to pharmaceutical companies who may be conducting clinical trials with Taxol..."
Later,
W2P